SILVER SPRING, MD, June 29, 2015 – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its technology and treatments will be featured on the Discovery Channel and ION Network tomorrow morning, June 30, 2015, from 7:00-7:30 a.m. EDT and PDT, except on DISH Network which airs using the EDT time zone. PharmaCyte Biotech’s story will air on Discovery Channel and ION Network’s news magazine series “NewsWatch,” a source for breaking consumer, technology, travel, health and entertainment news since 1990.
NewsWatch, based in the Washington, DC area, airs nationwide in the U.S. and can be seen in virtually every market throughout the country. Each edition of NewsWatch reaches more than 96 million U.S. households. Over 700 million people have viewed the NewsWatch series, making it one of the most successful independently produced news magazines on television. NewsWatch will present PharmaCyte Biotech’s story in “HealthWatch,” a segment that provides viewers with the latest medical breakthroughs and newest medical advances that can improve their health.
PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented, “We have a great story, and when we were contacted by NewsWatch to present our technology and the targeted treatments we’re developing for cancer and diabetes to their nationwide audience, we jumped at the opportunity. Our mission is about helping people. We can think of no better way to connect with people than to have our compelling story air on the Discovery Channel and ION Network and potentially be seen by the 96 million households they reach in the U.S.”
Since the series began in 1990, NewsWatch has featured more than 10,000 individual stories on a wide range of subjects, including medical breakthroughs, finance, travel, new product introductions, public policy issues, entertainment, celebrities and numerous other topics.